Lupin gets USFDA nod for hypertension drug
Lupin, one of the top pharmaceutical companies globally, has received a tentative approval from the US Food and Drug Administration to sell its high blood pressure treatment drug Olmesartan medoximil in the American market.
“It (Lupin) has received tentative (rpt) approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA),” a filing in BSE (Bombay Stock Exchange), from the company said.
The pharma major also said that Olmesartan medoximil tablets, generic version of Daiichi Sankyo’s Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure.
The Benicar tablets registered an annual sales of $1.06 billion in the US in 2016.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
